Azurity Archives
News and events as they happenAzurity Pharmaceuticals Acquires Slayback Pharma
MEDIA ALERT: Woburn, Mass. – September 27, 2023 – Azurity Pharmaceuticals, Inc. (“Azurity”) is pleased to announce the closing of its acquisition of Slayback Pharma LLC (“Slayback”) today from existing investors…
AZURITY PHARMACEUTICALS, INC. ANNOUNCES U.S. AVAILABILITY OF ZONISADE™ (zonisamide oral suspension)
MEDIA ALERT: Woburn, Mass. – October 12, 2022 – Azurity Pharmaceuticals, Inc., a private pharmaceutical company focused on developing innovative products to serve the specific needs of overlooked…
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF KONVOMEP™ (omeprazole and sodium bicarbonate for oral suspension)
Woburn, Mass. – September 2, 2022 – Azurity Pharmaceuticals, Inc., a private pharmaceutical company focused on developing innovative dose-forms and formulations of products to serve the needs of overlooked…
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF ZONISADE™ (zonisamide oral suspension)
Woburn, Mass. – July 18, 2022 – Azurity Pharmaceuticals, Inc., a private pharmaceutical company focused on developing innovative products to serve the specific needs of overlooked…